>Gaceta Médica de México
>Year 2015, Issue 2
Sánchez-Sánchez LM, Cabrera-Pedroza AU, Palacios-Saucedo G, de la Fuente-Cortez B
Zoledronic acid (zoledronate) in children with osteogenesis imperfecta (OI)
Gac Med Mex 2015; 151 (2)
PDF: 94.86 Kb.
Introduction: Zoledronic acid or zoledronate is a potent bisphosphonate that recently has been used in children with
osteoporosis and osteogenesis imperfecta (OI), so it could be an option in the treatment of children with this terrible
disease that virtually condemns them to a life of pain and prostration. The aim of this study was to evaluate the clinical
and biochemical conditions of pediatric patients with OI before and after treatment with zoledronate. Results: We
included 14 patients, median age six years (6 months to 14 years), eight (57.1%) males and six (42.9%) females,
weight 19 kg (5.8-45 kg). According to the type of OI, six (42.9%) were type I, six (42.9%) type III, and two (14.2%) type IV.
The functional score (Bleck) previous to treatment was 4 (1-9) and 6 (2-9) after treatment (p = 0.001). Pain intensity
prior to zoledronate was 2 (1-9) and 0 (0-2) after (p = 0.008). Previous fractures five (1-15) and post-treatment one (0-2)
(p = 0.001). There were no significant differences in calcium, phosphorus, alkaline phosphatase, and parathyroid hormone.
Conclusions: Zoledronic acid decreases the number of bone fractures and pain in children with osteogenesis imperfecta
and improves functional status. The most common side effects were fever and bone pain within five days after the infusion, which disappear with paracetamol. No adverse long-term effects such as hypocalcemia or hypoparathyroidism were reported.
||Osteogenesis imperfecta, Zoledronic acid, Zoledronate.
Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418): 1377-85.
Cheung MS, Glorieux FH. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008;9(2):153-60.
Sillence DO, Senn A, Danks DM. Genetic heterogenecity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101-16.
Van Dijik FS, Pals G, Van Rijn RR, et al. Classification of ostegenesis imperfecta revisited. Eur J Med Genet. 2010;53(1):1-5.
Rauch F, Lalic L, Glorieux FH. Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta. J Bone Miner Res. 2009;9999 (999A):1-30.
Antoniazzi F, Mottes M, Fraschini P, Tato L. Osteogenesis imperfecta: practical treatment guidelines. Paedriatr Drugs. 2000;2(6):465-88.
Davie MW, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis impefecta. Arch Dis Child. 1994;70(4):331-4.
Gloriueux FG. Treatment of osteogenesis imperfecta: who, why, what? Horm Res. 2007;68 Suppl 5:8-11.
Engelbert RH, Pruijis HE, Beemer FA. Osteogenesis imperfecta in childhood: treatment strategies. Arch Phys Med Rehabil. 1998;79(12):1590-4.
Bleck EE. Non operative treatment of osteogenesis impefecta: orthotic and mobility management. Clin Orth Rel Res. 1981;(159):111-22.
Esposito P, Plotkin H. Surgical treatment of osteogenesis imperfecta: current Concepts. Curr Opin Pediatr. 2008;20(1):52-7.
Rusell RG. Biophophonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150-62.
Allgrove J. Biphosphonates. Arch Dis Child. 1997;76(1):73-5.
Munns CF, Rausch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res. 2005;20(7):1235-43.
Phillipi CA, Remington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2008;(4):CD005088.
Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with olpadronate. Eur J Pediatr. 1997;156(10):792-4.
Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: 2 year randomsed placebo-controled study. Lancet. 2004;363(9419):1427-31.
Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics. 2007;119 Suppl 2:S163-5.
Brown JJ, Zacharin MR. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis. J Pediatr Endrocrinol Metab. 2009;22(1):55-63.
Almeida M, Uenis T, Guarniero R. The effect of zoledronate Turing bone Ealing. J Orthopaed Traumatol. 2010;11(1):7-12.
Panigrahi I, Das RR, Sharda S, Marwaha RK, Khandelwal N. Response to zoledronic acid in children with type III osteogenesis impefecta. J Bone Miner Metab. 2010;28(4):451-5.
Vuorimies I, Toivainen-Salo S, Hero M. Zoledronic acid in children with osteogenesis impefecta. Horm Res Peadiatr. 2011;75(5):546-53.
Kok D, Sakkers R, Janse A, et al. Quality of life in children with osteogenesis imperfecta treated with oral bisphosphonates (Olpadronate): a 2-year randomized placebo-controled trial. Eur J Pediatr. 2007;166(11): 1155-61.
Herreros F, Ascurra M. Las osteogenesis imperfectas: revisión del tema. Pediatr (Asuncion). 2008;35(1):33-7.
Lazala O, Solaque H. Terapia con bisfosfonatos en osteogenesis imperfecta. Rev Col Or Tra. 2009;23(2):109-14.
>Gaceta Médica de México
>Year 2015, Issue 2